Biotechnology company Allink Biotherapeutics has successfully completed a $42 million Series A financing. The financing round was led by Lanchi Ventures, with participation new investors including Yuanbio Venture Capital, Legend Capital and C&D Emerging Industry Equity Investment, alongside strong support from existing shareholders Gaorong Ventures and Med-Fine Capital. "Since our company's inception a little over […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!